International Journal of Head and Neck Surgery

Register      Login

VOLUME 13 , ISSUE 1 ( January-March, 2022 ) > List of Articles


Laryngopharyngeal Reflux

Bhagyashri Chiplunkar

Keywords : LPR, LPRD, RSI, RFS

Citation Information : Chiplunkar B. Laryngopharyngeal Reflux. Int J Head Neck Surg 2022; 13 (1):8-17.

DOI: 10.5005/jp-journals-10001-1519

License: CC BY-NC 4.0

Published Online: 25-05-2022

Copyright Statement:  Copyright © 2022; The Author(s).


  1. De Bortoli N, Nacci A, Savarino E, et al. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? World J Gastroenterol 2012;18(32):4363–4370. DOI: 10.3748/wjg.v18.i32.4363
  2. Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005;294(12):1534–1540. DOI:
  3. Cherry J, Margulies SJ. Contact ulcer of the larynx. Laryngoscope 1968;78(11):1937–1940. DOI: 10.1288/00005537-196811000-00007
  4. Koufman JA, Aviv JE, Casiano RR, et al. Laryngopharyngeal reflux: position statement of the Committee on Speech, Voice, and Swallowing Disorders of the American Academy of Otolaryngology – Head and Neck Surgery. Otolaryngol Head Neck Surg 2002;127:32–35. DOI: 10.1067/mhn.2002.125760
  5. Mittal RK, Balaban DH. The esophagogastric junction. N Engl J Med 1997;336(13):924–932. DOI:
  6. Stein. Possible mechanisms of influence of esophageal acid on airway hyperresponsiveness. Am J Med 2003;115(Suppl 3A):55S–59S. DOI: 10.1016/s0002-9343(03)00194-3
  7. Burton LK Jr, Murray JA, Thompson DM. Ear, nose, and throat manifestations of gastroesophageal reflux disease. Complaints can be telltale signs. Postgrad Med 2005;117(2):39–45. DOI: 10.3810/pgm.2005.02.1586
  8. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24–hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991;101(4 Pt2 Suppl 53):1–78. DOI: 10.1002/lary.1991.101.s53.1
  9. Milstein CF, Charbel S, Hicks DM, et al. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope). Laryngoscope 2005;115(12):2256–2261. DOI: 10.1097/01.mlg.0000184325.44968.b1
  10. Gill GA, Johnston N, Buda A, et al. Laryngeal epithelial defenses against laryngopharyngeal reflux: investigations of E-cadherin, carbonic anhydrase isoenzyme III, and pepsin. Ann Otol Rhinol Laryngol 2005;114(12):913–921. DOI: 10.1177/000348940511401204
  11. Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope 2001;111(8):1313–1317. DOI: 10.1097/00005537-200108000-00001
  12. Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope 2001;111(6):979–981. DOI: 10.1097/00005537-200106000-00009
  13. Belafsky PC, Postma GN, Amin MR, et al. Symptoms and findings of laryngopharyngeal reflux. Ear Nose Throat J 2002;81(9 Suppl 2):10–13.
  14. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice 2002;16(2):274–277. DOI: 10.1016/s0892-1997(02)00097-8
  15. Madan K, Ahuja V, Gupta SD, et al. Impact of 24-h esophageal pH monitoring on the diagnosis of gastroesophageal reflux disease: defining the gold standard. J Gastroenterol Hepatol 2005;20(1):30–37. DOI: 10.1111/j.1440-1746.2004.03530.x
  16. Franco RA Jr. Laryngopharyngeal reflux. In: Kunins L (Ed). UpToDate: Evidence-based Clinical Decision Support. Waltham, MA. Available at: Accessed March 30, 2018.
  17. Vaezi MF, Schroeder PL, Richter JE. Reproducibility of proximal probe pH parameters in 24-hour ambulatory esophageal pH monitoring. Am J Gastroenterol 1997;92(5):825–829.
  18. Reichel O, Issing WJ. Impact of different pH thresholds for 24-hour dual probe pH monitoring in patients with suspected laryngopharyngeal reflux. J Laryngol Otol 2008;122(5):485–489. DOI: 10.1017/S0022215107008390
  19. Lechien JR, Akst LM, Hamdan AL. Evaluation and management of laryngopharyngeal reflux disease: state of the art review. Otolaryngol Head Neck Surg 2019;160(5):762–782. DOI: 10.1177/0194599819827488
  20. Becker V, Graf S, Schlag C, et al. First agreement analysis and day-to-day comparison of pharyngeal pH monitoring with pH/impedance monitoring in patients with suspected laryngopharyngeal reflux. J Gastrointest Surg 2012;16:1096–1110. DOI: 10.1007/s11605-012-1866-x
  21. Chheda NN, Seybt MW, Schade RR, et al. Normal values for pharyngeal pH monitoring. Ann Otol Rhinol Laryngol 2009;118:166–171. DOI: 10.1177/000348940911800302
  22. Saritas Yuksel E, Hong SK, Strugala V, et al. Rapid salivary pepsin test: blinded assessment of test performance in gastroesophageal reflux disease. Laryngoscope 2012;122:1312–1316. DOI: 10.1002/lary.23252
  23. Wang J, Zhao Y, Ren J, et al. Pepsin in saliva as a diagnostic biomarker in laryngopharyngeal reflux: a meta-analysis. Eur Arch Otorhinolaryngol 2018;275:671–678. DOI: 10.1007/s00405-017-4845-8
  24. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000;6:S491–S505.
  25. Williams RB, Szczesniak MM, Maclean JC, et al. Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. Am J Gastroenterol 2004;99:777–785. DOI: 10.1111/j.1572-0241.2004.04151.x
  26. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000;18:20–26. DOI: 10.1159/000016930
  27. Anagha AJ, Bhagyashri GC, Renuka AB. Assessment of treatment response in patients with laryngopharyngeal reflux. Indian J Otolaryngol Head Neck Surg 2017;69(1):77–80. DOI: 10.1007/s12070-016-1046-5
  28. Koufman J, Sataloff RT, Toohill R. Laryngopharyngeal reflux: consensus conference report. J Voice 1996;10(3):215–216. DOI: 10.1016/s0892-1997(96)80001-4
  29. Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope 2001;111(12): 2147–2151. DOI: 10.1097/00005537-200112000-00013
  30. Richards DA. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. J Clin Gastroenterol 1983;5(Suppl 1): 81–90. DOI: 10.1097/00004836-198312001-00008
  31. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625–632. DOI: 10.1053/gast.2002.31876
  32. de Caestecker J. Prokinetics and reflux: a promise unfulfilled. Eur J Gastroenterol Hepatol 2002;14:5–7. DOI: 10.1097/00042737-200201000-00002
  33. Kahrilas PJ, Quigley EM, Castell DO, et al. The effects of tegaserod (HTF 919) on esophageal acid exposure in gastroesophageal reflux disease. Aliment Pharmacol Ther 2000;14(11):1503–1509. DOI: 10.1046/j.1365-2036.2000.00854.x
  34. McGlashan J, Johnstone L, Sykes J, et al. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol 2009;266: 243–251. DOI: 10.1007/s00405-008-0708-7
  35. Pearson J, Parikh S, Orlando R, et al. Review article: reflux and its consequences–the laryngeal, pulmonary and esophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston-upon-Hull, UK, 21–23 April 2010. Aliment Pharmacol Ther 2011;33(Suppl 1): 1–71. DOI: 10.1111/j.1365-2036.2011.04581.x
  36. Castell DO. Future medical therapy of reflux esophagitis. J Clin Gastroenterol 1986;8(Suppl 1):81–85.
  37. Storr M, Meining A, Allescher HD. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 2000;18:93–102. DOI: 10.1159/000016970
  38. Katz PO, Castell DO. Medical therapy of supraesophageal gastroesophageal reflux disease. Am J Med 2000;108(Suppl 4a): 170S–177S. DOI: 10.1016/s0002-9343(99)00359-9
  39. Zerbib F, Sifrim D, Tutuian R, et al. Modern medical and surgical management of difficult-to-treat GORD. United Eur Gastroenterol J 2013;1:21–31. DOI: 10.1177/2050640612473964
  40. Ciccaglione A, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastroesophageal reflux disease. Gut 2003;52:464–470. DOI: 10.1136/gut.52.4.464
  41. Eherer A, Netolitzky F, Hogenauer C, et al. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol 2012;107:372–378. DOI: 10.1038/ajg.2011.420
  42. Khalil H, Bridger M, Hilton-Pierce M, et al. The use of speech therapy in the treatment of globus pharyngeus patients. A randomised controlled trial. Rev Laryngol Otol Rhinol (Bord) 2003;124: 187–190.
  43. Hanson DG, Jiang JJ. Diagnosis and management of chronic laryngitis associated with reflux. Am J Med 2000;108(Suppl 4a):112S–119S. DOI: 10.1016/s0002-9343(99)00349-6
  44. Park W, Hicks DM, Khandwala F, et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pre-therapy predictors of response. Laryngoscope 2005;115:1230–1238. DOI: 10.1097/01.MLG.0000163746.81766.45
  45. Reavis KM, Morris CD, Gopal DV, et al. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms. Ann Surg 2004;239(6):849–848. DOI: 10.1097/
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.